Donald A. Berry

60.9k total citations · 21 hit papers
375 papers, 31.9k citations indexed

About

Donald A. Berry is a scholar working on Oncology, Cancer Research and Statistics and Probability. According to data from OpenAlex, Donald A. Berry has authored 375 papers receiving a total of 31.9k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 112 papers in Cancer Research and 104 papers in Statistics and Probability. Recurrent topics in Donald A. Berry's work include Statistical Methods in Clinical Trials (90 papers), Breast Cancer Treatment Studies (73 papers) and Cancer Genomics and Diagnostics (49 papers). Donald A. Berry is often cited by papers focused on Statistical Methods in Clinical Trials (90 papers), Breast Cancer Treatment Studies (73 papers) and Cancer Genomics and Diagnostics (49 papers). Donald A. Berry collaborates with scholars based in United States, United Kingdom and Canada. Donald A. Berry's co-authors include Constance Cirrincione, Hyman B. Muss, Eric P. Winer, Sheldon M. Ross, Clifford A. Hudis, Larry Norton, I. Craig Henderson, Eric J. Feuer, Kathleen A. Cronin and Kristine Broglio and has published in prestigious journals such as Nature, New England Journal of Medicine and JAMA.

In The Last Decade

Donald A. Berry

367 papers receiving 30.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer

2005 1.8k citations Donald A. Berry, Kathleen A. Cronin et al. profile →
Benefits and Harms of CT Screening for Lung Cancer

2012 927 citations Donald A. Berry et al. profile →
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

2003 921 citations I. Craig Henderson, Donald A. Berry et al. Journal of Clinical Oncology profile →
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

2002 883 citations Donald A. Berry, Daniel F. Hayes et al. Journal of Clinical Oncology profile →
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Donald A. Berry et al. Journal of Clinical Oncology profile →
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

2013 826 citations Jennifer R. Bellon, Constance Cirrincione et al. Journal of Clinical Oncology profile →
Introduction to Stochastic Dynamic Programming.

1986 814 citations Donald A. Berry et al. profile →
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

2010 809 citations Donald A. Berry et al. profile →
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 779 citations Hyman B. Muss, Ann D. Thor et al. profile →
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer

2004 733 citations Donald A. Berry, Constance Cirrincione et al. profile →
The Decrease in Breast-Cancer Incidence in 2003 in the United States

2007 682 citations Kathleen A. Cronin, Eric J. Feuer et al. profile →
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

2021 580 citations Donald A. Berry et al. profile →
Meta-analyses of colorectal cancer risk factors

2013 571 citations Constance Johnson, Joe Ensor et al. profile →
Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2

1998 540 citations Donald A. Berry et al. profile →
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

2006 518 citations Donald A. Berry, Constance Cirrincione et al. profile →
Probability and Statistics.

1978 493 citations Donald A. Berry et al. profile →
Addressing overdiagnosis and overtreatment in cancer: a prescription for change

2014 351 citations Donald A. Berry et al. profile →
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

2017 334 citations Donald A. Berry et al. profile →
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

2020 207 citations Donald A. Berry et al. profile →
Analysis of Breast Cancer Mortality in the US—1975 to 2019

2024 89 citations Jeanne S. Mandelblatt, Donald A. Berry et al. profile →

Peers

Countries citing papers authored by Donald A. Berry

Since Specialization

Citations

This map shows the geographic impact of Donald A. Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald A. Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald A. Berry more than expected).

Fields of papers citing papers by Donald A. Berry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald A. Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald A. Berry. The network helps show where Donald A. Berry may publish in the future.

Co-authorship network of co-authors of Donald A. Berry

This figure shows the co-authorship network connecting the top 25 collaborators of Donald A. Berry. A scholar is included among the top collaborators of Donald A. Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald A. Berry. Donald A. Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. 2024 ·Journal of Clinical Oncology ·John Frederick De Groot, Timothy F. Cloughesy, Donald A. Berry, Meredith Buxton, Howard Colman, Benjamin M. Ellingson, Gary Gordon, Andrew B. Lassman, Michael Lim, Ingo K. Mellinghoff, Erik P. Sulman, Michael Weller, Patrick Y. Wen, (unknown), Tom Mikkelsen, Scott Owen, Warren Mason, Jan Drappatz, (unknown), James Perry, (unknown)	0
2	Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. 2024 ·Journal of Clinical Oncology ·Barbara O’Brien, Rashmi K. Murthy, Donald A. Berry, Akshara Singareeka Raghavendra, Maria Gule-Monroe, Jason M. Johnson, (unknown), (unknown), (unknown), Michelle Melisko, Aki Morikawa, Sherise D. Ferguson, John Frederick De Groot, Ian E. Krop, Vicente Valero, Mothaffar F. Rimawi, Antonio C. Wolff, (unknown), Nancy U. Lin, Erica Stringer-Reasor	4
3	Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons 2023 ·Journal of Clinical Oncology ·Javier Oesterheld, William S. Ferguson, Jacqueline M. Kraveka, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Randal K. Wada, Michael S. Isakoff, Don Eslin, Valerie I. Brown, William Roberts, Peter E. Zage, (unknown), Deanna Mitchell, Derek Hanson, Giselle L. Saulnier Sholler	28
4	Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer 2020 ·Clinical Cancer Research ·Jim Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, (unknown), Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz‐Josef Lenz, (unknown), W. Michael Korn, David Spetzler	35
5	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer 2020 ·Journal of Clinical Oncology ·Aranzazu Fernández-Martínez, Ian E. Krop, David W. Hillman, Mei‐Yin C. Polley, Joel S. Parker, (unknown), Katherine A. Hoadley, Jonathan H. Shepherd, Sara M. Tolaney, N. Lynn Henry, Chau T. Dang, Lyndsay N. Harris, Donald A. Berry, Olwen Hahn, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Charles M. Perou, Lisa A. Carey	70
6	Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. 2017 ·Journal of Clinical Oncology ·Rita Nanda, Minetta C. Liu, Christina Yau, Smita Asare, Nola Hylton, Laura van’t Veer, Jane Perlmutter, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Anthony Elias, Donald A. Berry, Douglas Yee, Angela DeMichele, Laura Esserman	158
7	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) breakdown → 2014 ·Journal of Clinical Oncology ·William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance Cirrincione, Sara M. Tolaney, Charles Kuzma, Timothy Pluard, George Somlo, Elisa Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer	650
8	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses 2014 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Kenneth Aldape, (unknown), Razelle Kurzrock, Donald A. Berry	140
9	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative 2012 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock	387
10	Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009 2012 ·Clinical Cancer Research ·Filip Jankú, Donald A. Berry, Jing Gong, Henrique A. Parsons, David J. Stewart, Razelle Kurzrock	20
11	Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms (Annals of Internal Medicine (2009) 151, (738-747)) 2010 ·Annals of Internal Medicine ·Jeanne S. Mandelblatt, Kathleen A. Cronin, Stephanie Bailey, Donald A. Berry, Harry J. de Koning, Gerrit Draisma	24
12	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840 2008 ·Journal of Clinical Oncology ·Andrew D. Seidman, Donald A. Berry, Constance Cirrincione, Lyndsay N. Harris, Hyman B. Muss, P. Kelly Marcom, (unknown), Harold J. Burstein, Diana Lake, Charles L. Shapiro, Peter C. Ungaro, Larry Norton, Eric P. Winer, Clifford A. Hudis	446
13	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 2006 ·Breast Cancer Research ·Lyndsay N. Harris, Gloria Broadwater, Nancy U. Lin, Alexander Miron, Stuart J. Schnitt, David P. Cowan, Jonathan F. Lara, Ira J. Bleiweiss, Donald A. Berry, Matthew J. Ellis, Daniel F. Hayes, Eric P. Winer, Lynn Dressler	123
14	Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer 2006 ·Obstetrical & Gynecological Survey ·Donald A. Berry, Kathleen A. Cronin, Sylvia K. Plevritis, Dennis G. Fryback, Lauren Clarke, Marvin Zelen, Jeanne S. Mandelblatt, Andrei Y. Yakovlev, J. Dik F. Habbema, Eric J. Feuer	282
15	Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer 2006 ·Obstetrical & Gynecological Survey ·Donald A. Berry, Constance Cirrincione, I. Craig Henderson, Marc L. Citron, Daniel R. Budman, Lori J. Goldstein, Silvana Martino, Edith A. Perez, Hyman B. Muss, Larry Norton, Clifford A. Hudis, Eric P. Winer	24
16	An Informatics Tool to Assess Individualized Colon Cancer Risk 2005 ·Europe PMC (PubMed Central) ·Constance Johnson, Joe Ensor, Christopher I. Amos, Margaret R. Spitz, Susan K. Peterson, Bernard Levin, Donald A. Berry	2
17	Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients 2005 ·Journal of Clinical Oncology ·Lynn G. Dressler, Donald A. Berry, Gloria Broadwater, David P. Cowan, Kelly Cox, Stephanie Griffin, (unknown), (unknown), Debra B. Novotny, Diane L. Persons, Maurice Barcos, I. Craig Henderson, Edison T. Liu, Ann D. Thor, D. R. Budman, (unknown), Larry Norton, Daniel F. Hayes	82
18	Pre-Counseling Education Materials for BRCA Testing: Does Tailoring Make a Difference? 2002 ·Genetic Testing ·Celette Sugg Skinner, Joellen M. Schildkraut, Donald A. Berry, Brian Calingaert, P. Kelly Marcom, Jeremy Sugarman, Eric P. Winer, J. Dirk Iglehart, P. Andrew Futreal, Barbara K. Rimer	58
19	HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer 2000 ·Journal of Clinical Oncology ·Donald A. Berry, Hyman B. Muss, Ann D. Thor, Lynn Dressler, Edison T. Liu, Gloria Broadwater, D. R. Budman, I. Craig Henderson, Maurice Barcos, Daniel F. Hayes, Larry Norton	146
20	A case for Bayesianism in clinical trials (with discussion) 1993 ·Statistics in Medicine ·Donald A. Berry	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact